Next Article in Journal
Side Effects Related to Systemic Cancer Treatment: Are We Changing the Promethean Experience with Molecularly Targeted Therapies?
Previous Article in Journal
Sternal Resection for Recurrent Breast Cancer: A Cautionary Tale
 
 
Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
Journals
Current Oncology
Volume 15
Issue 4
10.3747/co.v15i4.228
curroncol-logo
Submit to this Journal Review for this Journal Propose a Special Issue
► Article Menu

Article Menu

share Share announcement Help format_quote Cite question_answer Discuss in SciProfiles thumb_up
...
Endorse textsms
...
Comment
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
first_page
settings
Order Article Reprints
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

Cetuximab Treatment in a Patient with Metastatic Colorectal Cancer and Psoriasis

by
B. Neyns
1,*,
V. Meert
2 and
F. Vandenbroucke
3
1
Department of Medical Oncology, Universitair Ziekenhuis Brussel, Brussels, Belgium
2
Department of Pathology, Universitair Ziekenhuis Brussel, Brussels, Belgium
3
Department of Radiology, Universitair Ziekenhuis Brussel, Brussels, Belgium
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2008, 15(4), 196-197; https://doi.org/10.3747/co.v15i4.228
Submission received: 8 May 2008 / Revised: 9 June 2008 / Accepted: 6 July 2008 / Published: 1 August 2008

Abstract

Cetuximab, a monoclonal antibody directed against the epidermal growth factor receptor, has activity against colorectal cancer. Treatment is associated with skin toxicity, and the safety of cetuximab in patients with psoriasis is unknown. We report the case of a male patient with stage IV colorectal cancer (CRC) and a life-long history of extensive psoriasis. This patient experienced a durable remission of his CRC and major improvement of his psoriasis during single-agent treatment with cetuximab. We conclude that, despite its known skin toxicity, cetuximab treatment can be offered to colorectal patients suffering from psoriasis.
Keywords: cetuximab; psoriasis; colorectal cancer; skin toxicity cetuximab; psoriasis; colorectal cancer; skin toxicity

Share and Cite

MDPI and ACS Style

Neyns, B.; Meert, V.; Vandenbroucke, F. Cetuximab Treatment in a Patient with Metastatic Colorectal Cancer and Psoriasis. Curr. Oncol. 2008, 15, 196-197. https://doi.org/10.3747/co.v15i4.228

AMA Style

Neyns B, Meert V, Vandenbroucke F. Cetuximab Treatment in a Patient with Metastatic Colorectal Cancer and Psoriasis. Current Oncology. 2008; 15(4):196-197. https://doi.org/10.3747/co.v15i4.228

Chicago/Turabian Style

Neyns, B., V. Meert, and F. Vandenbroucke. 2008. "Cetuximab Treatment in a Patient with Metastatic Colorectal Cancer and Psoriasis" Current Oncology 15, no. 4: 196-197. https://doi.org/10.3747/co.v15i4.228

APA Style

Neyns, B., Meert, V., & Vandenbroucke, F. (2008). Cetuximab Treatment in a Patient with Metastatic Colorectal Cancer and Psoriasis. Current Oncology, 15(4), 196-197. https://doi.org/10.3747/co.v15i4.228

Article Metrics

Back to TopTop